1638744-93-0Relevant academic research and scientific papers
THERAPEUTIC COMPOUNDS
-
Paragraph 00355; 00358-00359, (2021/06/04)
The present disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, and compositions and uses thereof. The compounds are useful as inhibitors of the YAP:TEAD protein:protein interaction. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various YAP:TEAD-mediated disorders, including cancer.
QUINAZOLINE COMPOUND FOR EGFR INHIBITION
-
Paragraph 0330; 0332, (2019/11/21)
Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.
TRIAZINONE COMPOUNDS
-
Paragraph 1324; 1325, (2014/08/06)
The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treati
Synthesis of enantiopure dehydropiperidinones from α-amino acids and alkynes via azetidin-3-ones
Ishida, Naoki,Yuhki, Tatsuya,Murakami, Masahiro
scheme or table, p. 3898 - 3901 (2012/09/22)
Chiral dehydropiperidinones were synthesized in enantiopure form from α-amino acids and alkynes via azetidin-3-ones.
Azetidin-3-ones from (S)-α-amino acids and their reactions with nucleophiles: Preparation of some azetidine-containing amino-alcohol and amino-acid derivatives
Podlech,Seebach
, p. 1238 - 1246 (2007/10/02)
The reactions of azetidin-3-ones 6-10, readily available from the amino acids L-alanine, L-phenylalanine, L-valine, L-lysine, and L-aspartic acid, via the corresponding diazo ketones, with nucleophilic reagents such as complex hydrides, Grignard compounds
